To require the coverage of testing for certain sexually transmitted infections without the imposition of cost sharing, and for other purposes.
Summary
HR9946, introduced by Rep. Nikema Williams, would require private health insurance plans to cover testing for certain sexually transmitted infections without cost-sharing. The bill is in early legislative stages, referred to five committees, and has no direct market impact as it does not authorize or appropriate funding. No publicly traded companies are directly affected by this mandate.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9946 is an early-stage bill with no funding authorization.
- 2.The bill mandates STI testing coverage without cost-sharing, affecting health insurers but not directly impacting publicly traded companies.
- 3.All sponsors are Democrats, indicating limited bipartisan support and low passage probability in the current Congress.
Market Implications
No direct market implications. The bill does not affect any publicly traded company's revenue or costs. Investors in health insurance companies like $UNH, $HUM, or $CI may see negligible indirect effects if the mandate increases utilization, but the impact is too small and uncertain to warrant action.
Full Analysis
HR9946 was introduced on July 23, 2026, and referred to five House committees: Energy and Commerce, Ways and Means, Veterans' Affairs, Armed Services, and Natural Resources. The bill mandates that group health plans and health insurance issuers cover testing for certain sexually transmitted infections (STIs) without imposing cost-sharing requirements. This is an early-stage bill with no funding authorization or appropriation. The legislative path is long: it must pass through multiple committees, the full House, the Senate, and be signed by The President. The bill's sponsor, Rep. Williams, is a junior member, and all 10 cosponsors are Democrats, indicating limited bipartisan momentum. No publicly traded companies are directly impacted because the bill imposes a coverage mandate on insurers, not on specific corporate entities. The mandate could increase utilization of STI testing services, but the revenue impact on diagnostic companies like $DGX or $LH is indirect and uncertain. The bill does not create a procurement program or tax incentive that would benefit a specific company. Given the early stage, lack of funding, and narrow scope, the market impact is negligible.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $874M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $903M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Proclamation: Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →